Variation in Bleomycin Hydrolase Gene Is Associated With Reduced Survival After Chemotherapy for Testicular Germ Cell Cancer | Zendy

De Haas | Zendy; Nynke Zwart | Zendy; Coby Meijer | Zendy; Janine Nuver | Zendy; H. Marike Boezen | Zendy; Albert J.H. Suurmeijer | Zendy; Harald J. Hoekstra | Zendy; Gerrit van der Steege | Zendy; Dirk Th. Sleijfer | Zendy; Jourik A. Gietema | Zendy

Open Access

Variation in Bleomycin Hydrolase Gene Is Associated With Reduced Survival After Chemotherapy for Testicular Germ Cell Cancer

Author(s) -

De Haas,

Nynke Zwart,

Coby Meijer,

Janine Nuver,

H. Marike Boezen,

Albert J.H. Suurmeijer,

Harald J. Hoekstra,

Gerrit van der Steege,

Dirk Th. Sleijfer,

Jourik A. Gietema

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.14.1606

Subject(s) - bleomycin , genotype , single nucleotide polymorphism , hazard ratio , oncology , medicine , proportional hazards model , testicular cancer , chemotherapy , snp , allele , cancer , cancer research , biology , gene , genetics , confidence interval

Response to chemotherapy may be determined by gene polymorphisms involved in metabolism of cytotoxic drugs. A plausible candidate is the gene for bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, an essential component of chemotherapy regimens for disseminated testicular germ-cell cancer (TC). We investigated whether the single nucleotide polymorphism (SNP) A1450G of the BLMH gene (rs1050565) is associated with survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research